How Medtronic’s Hugo Robotic-Assisted Surgery System Differentiates Itself in Urologic Procedures

Medtronic has received FDA clearance for its Hugo™ robotic-assisted surgery (RAS) system for minimally invasive urologic procedures, including prostatectomy, nephrectomy and cystectomy—procedures that represent roughly 230,000 surgeries each year in the United States. With this clearance, U.S. hospitals gain an alternative platform aimed at expanding robotic capacity and improving access to minimally invasive care.

Addressing Demand for Robotic Surgery
The United States leads global adoption of robotic surgeries, yet many hospitals face constraints in availability and program expansion. By entering the U.S. market with a system already used in tens of thousands of cases across more than 30 countries, Medtronic positions Hugo RAS as a solution designed to increase capacity and provide surgeons and hospitals with more choice in equipment and workflow design.

What Sets the Hugo RAS System Apart
Hugo RAS differentiates itself from incumbent robotic systems through a modular platform intended to maximize flexibility and utilization. Its robotic arms can be moved, positioned or shared across operating rooms to adapt to different procedural requirements and facility layouts. The open design of the surgeon console is intended to improve situational awareness, reduce physical strain, and support more effective real-time collaboration and training within surgical teams.

The system also builds on Medtronic’s broader digital ecosystem. Full integration with the Touch Surgery™ platform enables pre-operative simulation and training, real-time tele-proctoring, and AI-supported post-operative insights. Surgical teams can review case videos shortly after a procedure, supporting continuous improvement and cross-institution collaboration.

Medtronic’s established presence in open, laparoscopic, and robotic-assisted surgery gives it a unique multi-modality offering compared with competitors. Hospitals adopting Hugo RAS can leverage the company’s long-standing clinical expertise, training programs and portfolio of surgical instruments across modalities as robotic adoption grows.

Clinical Validation and Path to Broader Use
The system’s U.S. approval is supported by the Expand URO clinical study, the largest multi-port robotic-assisted urologic surgery trial completed in the country. The study demonstrated that Hugo RAS met safety and effectiveness endpoints with outcomes aligned with published benchmarks in robotic urology.

Following its urology clearance, Medtronic plans to pursue indications in general and gynecologic surgery, expanding the system’s footprint across additional specialties within the U.S. market.

Building an Integrated Surgical Ecosystem
With the introduction of Hugo RAS in the United States, Medtronic advances its strategy of offering a connected and integrated operating environment that links robotics, digital tools and surgical instrumentation. The system is positioned to support hospitals seeking scalable robotic programs and surgeons looking for flexible, data-enabled solutions to enhance procedural efficiency and patient outcomes.

www.medtronic.com